Gemcitabine is the standard care chemotherapeutic agent to treat
pancreatic cancer. Previously we demonstrated that
calcitriol (1, 25-dihydroxycholecalciferol) has significant anti-proliferative effects in vitro and in vivo in multiple
tumor models and enhances the activity of a variety of chemotherapeutic agents. We therefore investigated whether
calcitriol could potentiate the cytotoxic activity of
gemcitabine in the human
pancreatic cancer Capan-1 model system. Isobologram analysis revealed that
calcitriol and
gemcitabine had synergistic antiproliferative effect over a wide range of drug concentrations.
Calcitriol did not reduce the
cytidine deaminase activity in Capan-1
tumors nor in the livers of Capan-1
tumor bearing mice.
Calcitriol and
gemcitabine combination promoted apoptosis in Capan-1 cells compared with either agent alone. The combination treatment also increased the activation of caspases-8, -9, -6 and -3 in Capan-1 cells. This result was confirmed by substrate-based
caspase activity assay. Akt phosphorylation was reduced by
calcitriol and
gemcitabine combination treatment compared to single agent treatment. However, ERK1/2 phosphorylation was not modulated by either agent alone or by the combination.
Tumor regrowth delay studies showed that
calcitriol in combination with
gemcitabine resulted in a significant reduction of Capan-1
tumor volume compared to single agent treatment. Our study suggests that
calcitriol and
gemcitabine in combination promotes caspase-dependent apoptosis, which may contribute to increased anti-
tumor activity compared to either agent alone.